The antitussive pentoxyverine (POV) has a low proarrhythmic risk based on an in vitro and in vivo integrated risk assessment Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014
Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Clofazimine does not lead to significant QT interval prolongation: a multicentre study Source: Eur Respir J, 52 (5) 1801386; 10.1183/13993003.01386-2018 Year: 2018
Heart rate variability (HRV) and blood pressure (BP) changes in patients with neuromuscular disease (NMD) following setup of non-invasive ventilation (NIV) Source: Annual Congress 2013 –The heart of the matter: sleep disordered breathing Year: 2013
Clinical prediction of sleep apnoea – a tool for the selection of patients Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Signal-averaged electrocardiography (SAECG) in patients with pulmonary sarcoidosis (PS) Source: Eur Respir J 2001; 18: Suppl. 33, 345s Year: 2001
Cardiovascular risk evaluation using two different methods of pulse Wave analysis Source: Annual Congress 2013 –The heart of the matter: sleep disordered breathing Year: 2013
Short-term linear and nonlinear ("chaotic") characteristics of R-R interval dynamics in patients with sarcoidosis Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Respiratory polygraphy (RP) vs polysomnography (PSG) in the preoperative protocol of bariatric surgery: variability in the therapeutic decision. Source: International Congress 2019 – Diagnostic issues in obstructive sleep apnoea Year: 2019
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study Source: Eur Respir J, 52 (2) 1800537; 10.1183/13993003.00537-2018 Year: 2018
Prediction of cardiovascular risk from nocturnal pulse wave signal – Results from the ASIC multi center study Source: Annual Congress 2011 - Obstructive sleep apnoea : physiology, diagnostic tools and technology Year: 2011
Dynamics of QT interval from rest to peak exercise among COPD patients Source: International Congress 2014 – Clinical exercise physiology in health and COPD Year: 2014
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Improvement of detection of respiratory events (RE) and microarousals (A) using oxymetry pulse wave amplitude in sleep apnea syndrome (SAS) during polysomnography (PSG) Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006
Is it possible to check whether two measurements was performed on the same patient using pulsoximetric pulse wave signal characteristics? Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults II: questionnaires, epidemiology and sleep studies Year: 2015
Usefulness of standard end points of capsaicin cough challenge in health and disease Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope? Year: 2011